<DOC>
	<DOCNO>NCT02817945</DOCNO>
	<brief_summary>This open-label positron emission tomography/computed tomography ( PET/CT ) study investigate diagnostic performance evaluate efficacy 68Ga-NOTA-3PTATE-RGD lung cancer patient . A single dose 111-185 Mega-Becquerel ( MBq ) 68Ga-NOTA-3PTATE-RGD injected intravenously . Visual semiquantitative method use assess PET/CT image .</brief_summary>
	<brief_title>Dual Integrin αvβ3 SSTR2 Targeting PET Imaging Lung Cancer Patients</brief_title>
	<detailed_description>The number somatostatin receptor may greatly up-regulated cell variety tumor include carcinoid , gastrinomas , paragangliomas , small-cell lung cancer insulinomas . Octreotide eight amino acid cyclic peptide preserve four amino acid motif ( Phe-Trp-Lys-Thr ) critical biological activity somatostatin ( SSTR ) . On hand , RGD moiety bind integrin αvβ3 , also play important role regulation tumor growth , angiogenesis , local invasiveness , metastatic potential human lung cancer . To target receptor , heterodimeric peptide TATE-RGD synthesized TATE RGD glutamate linker label 68Ga . An open-label whole-body PET/ CT study design investigate safety dosimetry 68Ga-NOTA-3PTATE-RGD diagnostic performance 68Ga-NOTA-3PTATE-RGD PET/CT lung cancer patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Neoplasm identify Xray , ultrasound MRI lung cancer To provide basic information sign write informed consent . Consisted condition mental illness ; Severe liver kidney disease serum creatinine &gt; 3.0 mg/dl ( 270 μΜ ) hepatic enzyme level 5 time normal upper limit ; Severe allergy hypersensitivity IV radiographic contrast Claustrophobia accept PET/CT scan Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>TATE-RGD</keyword>
	<keyword>SSTR2</keyword>
	<keyword>integrin αvβ3</keyword>
</DOC>